Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Comparative efficacy of HIV regimens

Executive Summary

Highly-active antiretroviral therapy regimens that include non-nucleoside reverse transcriptase inhibitors were "modestly" better at virological suppression than protease inhibitor-based regimens, according to a direct meta-analysis of 12 trials conducted by the Oregon Evidence-based Practice Center. No difference was seen in death or disease progression or in withdrawal due to adverse events. However, the findings were complicated by an indirect analysis of 14 trials that included trials that were not head-to-head comparisons, which showed that NNRTI-based HAART was worse than PI-based regimens for virological suppression. The authors suggest that "indirect comparisons could be particularly unreliable for complex and rapidly evolving interventions such as HAART"...

You may also be interested in...

US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques

The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.

Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease

Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.

Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint

The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts